SSY Group (HKG:2005) obtained approval for the production and registration of the dronedarone hydrochloride tablets from China's National Medical Products Administration after it passed the regulator's consistency evaluation, a Wednesday Hong Kong bourse filing said.
The drug is a new antiarrhythmic drug and is mainly used for patients with sinus rhythm with a history of paroxysmal or persistent atrial fibrillation to reduce the risk of hospitalization due to atrial fibrillation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.